![David Liberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 13 195 $ al 31/07/2026
David Liberg is currently the Chief Scientific Officer at Cantargia AB. He previously worked as a Project Manager-Drug Development at Active Biotech AB.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CANTARGIA AB 0,02 % | 31/12/2024 | 69.087 ( 0,02 % ) | 13 195 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CANTARGIA AB | Director Técnico/Científico/I+D | 01/01/2015 |
| Empresas | Cargo | Fin |
|---|---|---|
| ACTIVE BIOTECH AB | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 2 |
|---|---|
Active Biotech AB
 Active Biotech AB BiotechnologyHealth Technology Develops drugs for cancer, neurodegenerative and inflammatory diseases | Health Technology |
Cantargia AB
 Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
